The results showed that DFS was significantly improved in patients receiving pembrolizumab in the all-comer population, regardless of PD-L1 expression, but PD-L1 TC ≥50% NSCLC patients did not exhibit a survival benefit (59, 61). The gene discussed is CD274; the disease is non-small cell lung carcinoma.